Literature DB >> 2872816

Rationale for the administration of opiate antagonists in treating infantile autism.

S I Deutsch.   

Abstract

A rationale exists for clinical trials of opiate antagonists in at least some patients with pervasive developmental disorders. An abnormality in levels of an endogenous opioid ligand, which may be partially corrected by neuroleptics, has been reported in the plasma of some autistic patients. Moreover, data suggesting that opiate antagonism may improve faulty attention and diminish the frequency of self-injurious behavior were reviewed. Opiate antagonists may prove useful for those autistic patients with a profile of inattentiveness and self-injurious behavior. Also, these agents may act synergistically with neuroleptics.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2872816

Source DB:  PubMed          Journal:  Am J Ment Defic        ISSN: 0002-9351


  5 in total

1.  Brief report: a double-blind study of naltrexone in infantile autism.

Authors:  M Leboyer; M P Bouvard; J M Launay; F Tabuteau; D Waller; M Dugas; B Kerdelhue; P Lensing; J Panksepp
Journal:  J Autism Dev Disord       Date:  1992-06

2.  Brief report: a synopsis of an open-trial of naltrexone treatment of autism with four children.

Authors:  J Panksepp; P Lensing
Journal:  J Autism Dev Disord       Date:  1991-06

3.  A case report of naltrexone treatment of self-injury and social withdrawal in autism.

Authors:  A S Walters; R P Barrett; C Feinstein; A Mercurio; W T Hole
Journal:  J Autism Dev Disord       Date:  1990-06

Review 4.  An urgent need for experimental animal model of autism in drug development.

Authors:  Rakesh K Ruhela; Ajay Prakash; Bikash Medhi
Journal:  Ann Neurosci       Date:  2015-01

5.  High complement factor I activity in the plasma of children with autism spectrum disorders.

Authors:  Naghi Momeni; Lars Brudin; Fatemeh Behnia; Berit Nordström; Ali Yosefi-Oudarji; Bengt Sivberg; Mohammad T Joghataei; Bengt L Persson
Journal:  Autism Res Treat       Date:  2011-10-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.